Flu Shots and Vaccines

The 2024-2025 flu season appears to be a nasty one. Data released by the Centers for Disease Control and Prevention show a rising number of visits to healthcare facilities to treat flu symptoms.

The CDC reports clinical labs found the flu virus in nearly 32% of the specimens that were submitted for analysis. 

“As of February 7, 2025, the amount of acute respiratory illness causing people to seek healthcare is at a very high level,” the CDC said. “Seasonal influenza activity remains elevated and continues to increase across the country.”

According to the CDC, 7.8% of visits to healthcare providers in the last week were for treatment of a respiratory illness, an increase from the previous week. The health agency also reported an increase in the number of COVID-19 cases but said cases of RSV were declining.

The CDC also monitors viral activity in wastewater across the U.S. to gauge the severity of a respiratory outbreak. Its latest analysis found “very high” levels of influenza presence, “high” levels of COVID-19 and a “moderate” level of RSV.

In the United States, flu season usually occurs in the fall and winter. While influenza viruses spread year-round, most of the time flu activity peaks between December and February. As the CDC chart below graphically illustrates, February is usually the peak month for infections.

Serious cases of influenza should be treated by a healthcare professional. For less severe cases, the Mayo Clinic suggests these treatments may provide relief:

• Drink plenty of liquids. Choose water, juice and warm soups to help keep fluids in your body.

• Rest. Get more sleep to help your immune system fight infection. You may need to change your activity level, depending on your symptoms.

• Consider pain relievers. Use acetaminophen (Tylenol, others) or ibuprofen (Advil, Motrin IB, others) for fever, headache or achiness associated with influenza. Children and teens recovering from flu-like symptoms should never take aspirin because of the risk of Reye's syndrome, a rare but potentially fatal condition.

A new study conducted by researchers from McMasters University explored the effectiveness of different types of vaccines delivered through the respiratory system. Their findings showed that inhaled vaccines are likely to reach deeper into the respiratory system, which makes them more effective than nasal spray vaccines. 

“Infections in the upper respiratory tract tend to be non-severe,” said researcher Matthew Miller. “In the context of infections caused by viruses like influenza or SARS-CoV-2, it tends to be when the virus gets deep into the lung that it makes you really sick. 

“The immune response you generate when you deliver the vaccine deep into the lung is much stronger than when you only deposit that material in the nose and throat because of the anatomy and nature of the tissue and the immune cells that are available to respond are very different.”  

Better protection from viruses

The researchers put different types of vaccines to the test on animals. They used both an inhaled and nasal spray tuberculosis vaccine and compared the immune responses, general potency of the vaccines, and the distribution of droplets in the animals. 

While both vaccines proved to be effective, the inhaled vaccine provided a much stronger immune response. The researchers explained that the nasal spray vaccine travels to the nose and throat but doesn’t go much further than that in the body. 

The study showed that the inhaled tuberculosis vaccine was more effective because it was able to reach deeper into the respiratory system. With the inhaled vaccine, the immune droplets never settled in the nasal passages. Instead, they traveled farther into the lungs. 

The researchers are currently in the middle of clinical trials that are testing an inhaled COVID-19 vaccine that would work in this way by targeting the respiratory system. 

“This study for the first time provides strong preclinical evidence to support the development of inhaled aerosol delivery over nasal spray for human vaccination against respiratory infections including TB, COVID-19, and influenza,” said researcher Zhou Xing. 

In its mission to keep as many people healthy and safe as possible, Pfizer has announced a major goodwill effort that it calls “Accord for a Healthier World”.

The initiative will provide all of Pfizer's current and future patent-protected medicines and vaccines on a not-for-profit basis to 45 lower-income countries. By taking this step, the company says it could close the health equity gap for more than a billion people.

Rwanda, Ghana, Malawi, Senegal, and Uganda are the first five countries that have committed to joining the Accord. Health officials in these countries will help spot and resolve any hurdles that Pfizer may face so that the company can learn and enhance the rollout in the rest of the lower-income countries.

“As we learned in the global COVID-19 vaccine rollout, supply is only the first step to helping patients. We will work closely with global health leaders to make improvements in diagnosis, education, infrastructure, storage and more. Only when all the obstacles are overcome can we end healthcare inequities and deliver for all patients,” said Pfizer Chairman and Chief Executive Officer Albert Bourla.

The types of medicines Pfizer is providing

Pfizer says its commitment includes 23 medicines and vaccines that treat infectious diseases, certain cancers, and rare and inflammatory diseases. These diseases and conditions affect millions of lives each year in the countries the Accord will serve. As Pfizer develops and launches new medicines and vaccines, it will also make those products available on a not-for-profit basis.

One particular focus will be on Group B Streptococcus, a bacteria that commonly lives in people’s gastrointestinal and genital tracts. The Centers for Disease Control and Prevention (CDC) says the bacteria is not harmful and doesn't make people feel sick most of the time, but it is a leading cause of stillbirth and newborn mortality in low-income countries. Working with the Bill and Melinda Gates Foundation, Pfizer is also discussing opportunities to support Respiratory Syncytial Virus (RSV) vaccine development.

“Everyone, no matter where they live, should have the same access to innovative, life-saving drugs and vaccines,” Bill Gates said. “The Accord for a Healthier World could help millions more people in low-income countries get the tools they need to live a healthy life. Pfizer is setting an example for other companies to follow.”